T 1095

Drug Profile

T 1095

Alternative Names: RWJ 394718

Latest Information Update: 02 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Johnson & Johnson; Tanabe Seiyaku
  • Class Antihyperglycaemics; Glucosides
  • Mechanism of Action Sodium-glucose transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 12 Jan 2004 Tanabe Seiyaku is switching development to a backup compound
  • 25 Jun 2003 Data presented at the 63rd Scientific Sessions of the American Diabetes Association (ADA-2003) have been added to the Diabetes mellitus pharmacodynamics section
  • 16 Oct 2002 Phase-II clinical trials in Diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top